Live price temporarily unavailable.
Zentalis Pharmaceuticals (ZNTL) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | — | $0 | $0 | $67.4M | $0 |
| Growth (year over year) | — | — | — | — | — | — | −100.0% |
| Operating income | −$46.8M | −$118.8M | −$216.5M | −$227.3M | −$299.5M | −$191.2M | −$152.8M |
| Operating margin | — | — | — | — | — | −283.6% | — |
| Net income | −$45.7M | −$117.8M | −$158.7M | −$236.8M | −$292.2M | −$165.8M | −$137.1M |
| Net margin | — | — | — | — | — | −246.0% | — |
| EPS (diluted) | −$8.16 | −$4.19 | −$3.72 | −$4.48 | −$4.47 | −$2.33 | −$1.91 |
| Balance sheet | |||||||
| Cash and equivalents | $67.2M | $55.0M | $59.7M | $43.1M | $28.0M | $33.9M | $36.0M |
| Total assets | $87.5M | $365.6M | $454.5M | $539.3M | $551.7M | $430.3M | $289.0M |
| Total liabilities | $19.1M | $32.2M | $90.0M | $105.3M | $114.3M | $93.2M | $72.8M |
| Shareholders' equity | −$73.3M | $308.6M | $364.0M | $433.8M | $437.3M | $337.2M | $216.2M |
| Cash flow | |||||||
| Operating cash flow | −$39.1M | −$86.8M | −$154.1M | −$163.8M | −$207.8M | −$170.9M | −$125.2M |
| Capital expenditure | $352.0K | $758.0K | $6.11M | $2.55M | $583.0K | $221.0K | $0 |
| Free cash flow | −$39.5M | −$87.6M | −$160.2M | −$166.3M | −$208.4M | −$171.1M | −$125.2M |
| Share buybacks | — | — | — | — | $0 | $0 | $9.98M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $26.9M | $0 | $0 | $0 | — | — | — |
| Growth (year over year) | — | — | −100.0% | — | — | — | — | — |
| Operating income | −$51.4M | −$49.8M | −$45.6M | −$36.1M | −$33.7M | — | −$37.9M | −$44.4M |
| Operating margin | — | −185.6% | — | — | — | — | — | — |
| Net income | −$40.2M | −$47.5M | −$48.3M | −$26.9M | −$26.7M | — | −$35.4M | −$42.3M |
| Net margin | — | −176.7% | — | — | — | — | — | — |
| EPS (diluted) | −$0.56 | −$0.67 | −$0.67 | −$0.37 | −$0.37 | — | −$0.50 | −$0.59 |
| Balance sheet | ||||||||
| Cash and equivalents | $41.3M | $33.9M | $41.9M | $37.6M | $39.1M | $36.0M | $31.9M | $24.8M |
| Total assets | $450.7M | $430.3M | $384.0M | $351.7M | $327.3M | $289.0M | $253.1M | $215.3M |
| Total liabilities | $96.3M | $93.2M | $88.6M | $77.2M | $74.4M | $72.8M | $70.4M | $71.7M |
| Shareholders' equity | $354.3M | $337.2M | $295.4M | $274.5M | $252.9M | $216.2M | $182.7M | $143.6M |
| Cash flow | ||||||||
| Operating cash flow | −$44.0M | −$39.7M | −$32.6M | −$34.7M | −$27.0M | — | −$33.0M | −$37.2M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 | — | $34.0K | $0 |
| Free cash flow | −$44.0M | −$39.7M | −$32.6M | −$34.7M | −$27.0M | — | −$33.0M | −$37.2M |
From Zentalis Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Zentalis Pharmaceuticals in our feed yet.